A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2001
11/13/2001	US6316466 Pyrazole derivatives P-38 MAP kinase inhibitors
11/13/2001	US6316465 Ophthalmic uses of PPARgamma agonists and PPARgamma antagonists
11/13/2001	US6316464 P38 MAP kinase inhibitors
11/13/2001	US6316462 Methods of inducing cancer cell death and tumor regression
11/13/2001	US6316461 Antipruritic
11/13/2001	US6316460 Containing a heptenoic acid derivative and a tribasic phosphate salt as a stabilizer; hmg-coa reductase inhibitor
11/13/2001	US6316458 Method of enhancing insulin action
11/13/2001	US6316457 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
11/13/2001	US6316456 Purine derivatives having, in particular, antiproliferative properties, and their biological uses
11/13/2001	US6316455 Method of improving the effectiveness of a cytotoxic drug or radiotherapy using a quinazolinone compound
11/13/2001	US6316454 Inducing apoptosis and preventing metastases of brain tumor cells
11/13/2001	US6316453 Aqueous pharmaceutical composition
11/13/2001	US6316451 Heterocyclyl anthracyclinone derivatives
11/13/2001	US6316450 Compounds
11/13/2001	US6316448 Pyrazolo[3,4-d][1,2,3] troazines having anticonvulsant activity and process for their preparation
11/13/2001	US6316446 Fungicidal mixture
11/13/2001	US6316444 SRC kinase inhibitor compounds
11/13/2001	US6316443 Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
11/13/2001	US6316441 Brinzolamide and brimonidine for treating glaucoma
11/13/2001	US6316439 Galanthamine derivatives as acetylcholinesterase inhibitors
11/13/2001	US6316438 Fused pyridopyridazine inhibitors of cGMP phosphodiesterase
11/13/2001	US6316437 Spirohydantoin compounds and uses thereof
11/13/2001	US6316435 Combination therapy for lymphoproliferative diseases
11/13/2001	US6316433 Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
11/13/2001	US6316432 Antigestagenically active steroids with a flourinated 17 α-alkyl chain
11/13/2001	US6316431 Use of an aromatase inhibitor in the treatment of decreased androgen to estrogen ratio and detrusor urethral sphincter dyssynergia in men and method to study the dyssynergia in male rodents
11/13/2001	US6316428 Topical moisturizing composition and method
11/13/2001	US6316427 Antidiabetics agents and ingestion of time release starch at bedtime
11/13/2001	US6316426 Nucleoside derivative for diabetes, heart disease, cerebrovascular disorders, parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis
11/13/2001	US6316425 Therapeutic agents
11/13/2001	US6316424 Sulfated phosphatidylinositols, their preparation and use of the same
11/13/2001	US6316423 Method of treating ischemic, hypoxic and anoxic brain damage
11/13/2001	US6316422 Compounds related to the amidinium family, pharmaceutical compositions containing same, and uses thereof
11/13/2001	US6316417 Parenteral formulations comprising carbamazepine or its derivatives
11/13/2001	US6316416 Uteroglobin therapy for epithelial cell cancer
11/13/2001	US6316415 Sulfonamide interleukin-1β converting enzyme inhibitors
11/13/2001	US6316409 Modified ligands of calcium-dependent binding proteins
11/13/2001	US6316408 Methods of use for osetoprotegerin binding protein receptors
11/13/2001	US6316404 Treatment of non-insulin-dependent diabetes mellitus using an rxr agonist alone or in combination with a ppar.gamma. agonist such as a thiazolidinedione compound.
11/13/2001	US6316403 Deactivation of factor ix for coagulation inhibition and antiischemic agents
11/13/2001	US6316259 Antisense inhibition of glycogen synthase kinase 3 alpha expression
11/13/2001	US6316239 HKABY60 kinase family polypeptides
11/13/2001	US6316219 Compounds
11/13/2001	US6316214 ETM-775 metabolite of ecteinascidin 743
11/13/2001	US6316203 Methods of screening and preparing a composition using DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
11/13/2001	US6316038 Therapeutic compositions
11/13/2001	US6316033 Compositions for treatment of antibiotic-resistant gram-positive bacterial infections and methods for using and preparing the same
11/13/2001	US6316031 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
11/13/2001	US6316030 Use of nanoscale sterols and sterol esters
11/13/2001	US6316029 Rapidly disintegrating solid oral dosage form
11/13/2001	US6316027 Fast-dissolving dosage forms for dopamine agonists
11/13/2001	US6316025 Absorption upon digestion
11/13/2001	US6316023 TTS containing an antioxidant
11/13/2001	US6316022 Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
11/13/2001	US6316020 For therapy of gastric acid related diseases in mammals
11/13/2001	US6316009 Biphenyl derivatives substituted by an aromatic or heteroaromatic radical and pharamaceutical and cosmetic compositions containing same
11/13/2001	US6316007 Combined physical and immunotherapy for cancer
11/13/2001	US6316001 Method for treatment of psoriasis
11/13/2001	US6315998 Administering anti-cd40 monoclonal antibody or an antigen binding fragment which is being free of significant agonistic activity and binding to a human cd40 antigen located on surface of a human b cell prevents growth or differentiation
11/13/2001	US6315995 Adding to blood inactive recombinant mutein comprising proteolytically inactive mutein of factor ix or ixa to inhibit clot formation, does not interfere with hemostasis when the blood is administered to a patient
11/13/2001	US6315985 C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
11/13/2001	US6315983 Process for the production of powdered pulmonary surfactant preparations
11/13/2001	US6315980 Applying predetermined stress to model experimental animal, in a system to which tested fragrance is not applied, to reduce skin barrier function of animal and using this data of degree of recovery of skin barrier function for evaluation
11/13/2001	US6315978 Bioconjugates and delivery of bioactive agents
11/13/2001	US6315756 Tumescent solution
11/13/2001	US6314956 Treating lung defects associated hypoxemia or smooth muscle constriction; administer ethyl nitrite to human and monitor
11/13/2001	CA2171728C Triaryl-ethylene derivatives for use in therapy
11/13/2001	CA2161869C N-alkylthio polyamine derivatives as radioprotective agents
11/13/2001	CA2064793C Hydrolytic enzyme inhibitors and substrates and assays, methods and kits embodying same
11/12/2001	CA2347566A1 Solid compositions exhibiting selective binding to dissolved iron
11/12/2001	CA2347442A1 Free radical scavenging compositions
11/11/2001	CA2347301A1 Proanthocyanidins and ascorbic acid composition for topical application to human respiratory and oral mucosa
11/11/2001	CA2345787A1 Biocompatible macromers
11/08/2001	WO2001083740A2 Splice-region antisense composition and method
11/08/2001	WO2001083714A2 Composition and methods for treating photoreceptor degeneration
11/08/2001	WO2001083698A2 Compositions and methods for inducing activation of dendritic cells
11/08/2001	WO2001083560A1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
11/08/2001	WO2001083522A2 Growth factor modified protein matrices for tissue engineering
11/08/2001	WO2001083514A2 Nucleic acids encoding a regulator of a g protein signaling, rgs18, and uses thereof
11/08/2001	WO2001083513A2 Antisense modulation of inhibitor of dna binding-1 expression
11/08/2001	WO2001083512A1 3-nitrogen-6,7-dioxygen steroids and uses related thereto
11/08/2001	WO2001083508A1 Antisense modulation of zinc finger protein-217 expression
11/08/2001	WO2001083503A2 MODULATION OF OLIGONUCLEOTIDE CpG-MEDIATED IMMUNE STIMULATION BY POSITIONAL MODIFICATION OF NUCLEOSIDES
11/08/2001	WO2001083501A1 Anti-viral pyrimidine nucleoside analogues
11/08/2001	WO2001083497A1 Cyclipostins, a method for their production and the use of the same
11/08/2001	WO2001083496A1 Bis-(n,n'-bis-(2-haloethyl)amino) phosphoramidates as antitumor agents
11/08/2001	WO2001083489A1 THIENO[2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS
11/08/2001	WO2001083486A1 Tricyclic fused pyridine and pyrimidine derivatives as crf receptor antagonists
11/08/2001	WO2001083484A1 Pyrano, piperidino, and thiopyrano compounds and methods of use
11/08/2001	WO2001083483A1 (5R)-(METHYLAMINO)-5,6-DIHYDRO-4H-IMIDAZO[4,5,1-ij]QUINOLINE-2(1H)-THIONE
11/08/2001	WO2001083480A2 Dihydropyridine compounds and methods of use
11/08/2001	WO2001083479A2 Process for the preparation of pyrazolopyridine derivatives
11/08/2001	WO2001083478A2 Hydantoin-containing glucokinase activators
11/08/2001	WO2001083477A1 Stolonoxides
11/08/2001	WO2001083476A1 Chromenylmethyl pyrimidinediamines as antibacterial agents
11/08/2001	WO2001083475A1 Novel heterocyclic compounds with anti-inflammatory activity
11/08/2001	WO2001083474A1 Pyrimidinyl methyl indole derivatives with antibacterial activity
11/08/2001	WO2001083473A1 Process for producing optically active sulfoxide derivative
11/08/2001	WO2001083472A1 Muscarinic agonists
11/08/2001	WO2001083470A1 Sodium-hydrogen exchanger type 1 inhibitor (nhe-1)

1 ... 5970 5971 5972 5973 5974 5975 5976 5977 5978 5979 5980 5981 5982 5983 5984 5985 5986 5987 5988 5989 5990 ... 7860